Roche is moving forward with Santaris' LNA-based antagonist of HIF-1 alpha, but has not decided on the future of a Phase II microRNA-target HCV drug candidate.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a num

This story has been updated to include additional comment from Roche.

A US District Court last week denied Santaris Pharma's second bid to have a patent-infringement lawsuit filed against it by Isis Pharmaceuticals thrown out, ruling that the company again failed to establish that its allegedly infringing activities were protected by a US statute t

A team of Spanish researchers this week published a new report implicating microRNA-21 in psoriasis and demonstrating that 8-mer locked nucleic acids targeting the miRNA could improve symptoms of the disease in a mouse model.

Title: Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
Patent Number: 8,652,526
Filed: April 4, 2012

Isis Pharmaceuticals this month took issue with Santaris Pharma's latest attempt to use a safe harbor provision in US law to fend off patent infringement charges in the companies' ongoing legal war, arguing in a court filing that the legal protection only covers the development o

While the top publicly traded RNAi therapeutics developers took great strides this year in getting drug candidates into the clinic, and were rewarded by Wall S

Santaris Pharma last week made another push to end the legal attack against it by Isis Pharmaceuticals, asking for the court that is hearing the companies' intellectual property lawsuit to rule that there was no infringement of the patents at the heart of the case.


360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.